Evidence map›Paper›PMID 38956906›Full record

ArticleCurrent cancer drug targets2025

Low Expression of SCN4B Predicts Poor Prognosis in Non-small Cell Lung Cancer.

Xia Li, Weiwei Chen, Shu Jiang, Lianlian Zhang, Hua Huang, Yanan Ji, Qinggan Ni, Chunhua Ling

Abstract read
PubMed Publisher
In one paragraph

Article in Current cancer drug targets, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xia LiDepartment of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou, 215006, PR China.
Weiwei ChenDepartment of Radiation Therapy, Affiliated Hospital 6 of Nantong University, Yancheng Third People's Hospital, Yancheng, 224000, PR China.
Shu JiangDepartment of Magnetic Resonance, Yancheng Clinical College of Xuzhou Medical University, Yancheng No 1 people's Hospital, Yancheng, 224000, PR China.
Lianlian ZhangDepartment of Ultrasound Imaging, Yancheng Clinical College of Xuzhou Medical University, Yancheng No 1 people's Hospital, Yancheng, 224000, PR China.
Hua HuangDepartment of Pathology, Affiliated Hospital of Nantong University, Nantong, 226001, Jiangsu, China.
Yanan JiThe Central Laboratory, Affiliated Hospital 6 of Nantong University, Yancheng Third People's Hospital, Yancheng, 224000, PR China.
Qinggan NiDepartment of Burns and Plastic Surgery, Yancheng Clinical College of Xuzhou Medical University, The First people's Hospital of Yancheng, Yancheng, 224000, PR China.
Chunhua LingDepartment of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou, 215006, PR China.

Funding

Jiangsu Provincial Health and Health Commission Medical Research Guidance Project Z2021087Nantong University's 2023 Academic Level Research Project (Special Project of Yancheng Third Institute) YXY-Z2023008Special Funds for Science Development of the Clinical Teaching Hospitals of Jiangsu Vocational College of Medicine 20209113, 20219105Yancheng Medical Science and Technology Development Plan Project YK2021060
6 · The paper itself

Abstract

backgroundSodium voltage-gated channel beta subunit 4 (SCN4B) plays a suppressive role in various tumors. However, the role of SCN4B in non-small cell lung cancer (NSCLC) is not yet clear. This study aims to investigate the expression of SCN4B in NSCLC patients and its correlation with prognosis.

methodsFirstly, the expression of SCN4B in non-small cell lung cancer (NSCLC) was analyzed using The Cancer Genome Atlas (TCGA) database. Then, differential expression genes (DEGs) were identified using R software. Next, DEG enrichment pathways were analyzed using the R package clusterProfiler. Protein-protein interaction networks were revealed through STRING analysis. A heatmap showed significant differential expression of SCN4B. Further analysis included examining SCN4B expression in a pan-cancer context and its correlation with 24 types of immune cells in NSCLC. Subsequently, quantitative real-time polymerase chain reaction (qRT-PCR), Western Blot, immunohistochemistry, and clinical data were used to validate SCN4B expression and prognostic value in NSCLC patients.

resultsSCN4B mRNA expression in non-small cell lung cancer tissues was significantly lower than in adjacent normal tissues (p < 0.001). Clinical correlation analysis confirmed its association with clinical pathology. Gene set enrichment analysis (GSEA) and tumor immune-related analyses indicated that SCN4B is involved in NSCLC-related Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways and participates in immune infiltration. qRT-PCR, Western Blot, and immunohistochemistry also confirmed that SCN4B is downregulated in NSCLC patients and is associated with poor prognosis.

conclusionSCN4B is downregulated in tumor tissues of NSCLC patients and is associated with a poor prognosis.

Indexed as

Biomarkers, TumorCarcinoma, Non-Small-Cell LungLung NeoplasmsVoltage-Gated Sodium Channel beta-4 SubunitFemaleGene Expression Regulation, NeoplasticHumansMaleMiddle AgedPrognosisProtein Interaction MapsBiomarkers, TumorSCN4B protein, humanVoltage-Gated Sodium Channel beta-4 SubunitalmonertinibEGFR-TKIsicotinibinterstitial lung diseaseLung adenocarcinomaSCN4B.

Identifiers

PMID38956906

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.